| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8524717 | Biomedicine & Pharmacotherapy | 2018 | 7 Pages |
Abstract
Recombinant OA treated BMSC exerted better osteogenesis potency even with Dex administration. This is because additional OA in medium counter-acts with Dex's influence and rescued osteoblast differentiation via up-regulating integrin β1 and activate ERK/MAPK pathway which promotes osteogenesis. Hence, OA/integrin β1 could serve as potential therapeutic target for OP.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
He Hu, Zhehai Li, Min Lu, Xinyi Yun, Wei Li, Caiyun Liu, Ai Guo,